Pediatric multiple sclerosis: Escalation and emerging treatments

Area of Science:

• Neurology
• Pediatric Medicine
• Clinical Pharmacology

Background:

• Significant advances in multiple sclerosis (MS) therapeutics for adults have occurred over the last 20 years.
• Therapeutic options for pediatric patients with MS are limited, with only a few disease-modifying therapies approved for older children.
• Availability of MS treatments for children and adolescents varies globally, with significant limitations in some regions.

Purpose of the Study:

• To review current knowledge on managing breakthrough disease, escalation, and induction treatment approaches in pediatric MS.
• To discuss disease course and disability outcomes in children and adolescents with MS.
• To summarize ongoing clinical trials and address challenges in pediatric MS research.

Main Methods:

• Review of current literature on pediatric multiple sclerosis treatment.
• Analysis of recent legislation mandating pediatric studies for new therapeutics.
• Summary of ongoing clinical trials and their methodologies.

Main Results:

• Up to 30% of children with MS experience breakthrough disease, necessitating advanced therapies.
• Recent legislation in the US and Europe mandates clinical studies for pediatric applicability of new therapeutics.
• Several clinical trials are currently investigating the efficacy and safety of newer drugs in pediatric MS.

Conclusions:

• There is a critical need for expanded therapeutic options and research for pediatric multiple sclerosis.
• Ongoing clinical trials are crucial for understanding and improving treatment strategies for children and adolescents with MS.
• Addressing challenges in pediatric clinical trials is essential for advancing care and improving outcomes.